Sleep quality in efavirenz-treated Chinese HIV patients - comparing between GT and GG genotype of CYP2B6-516 G/T polymorphisms

International Journal of STD and AIDS

Volumn 25, Issue 3, 2014, Pages 193-200

  Lee, Shui Shan ^a   To, Kin Wang ^a   Lee, Man Po ^b   Wong, Ngai Sze ^a   Chan, Denise PC ^a   Li, Patrick CK ^b   Cheung, Siu Wai ^a   Chan, Raphael CY ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

AIDS; antiretroviral therapy; CYP2B6; efavirenz; HIV; pharmacogenetics; Pittsburgh sleep quality index; sleep quality; therapeutic drug monitoring

Indexed keywords

AIDS; ANTIRETROVIRAL THERAPY; CYP2B6; EFAVIRENZ; HIV; PHARMACOGENETICS; PITTSBURGH SLEEP QUALITY INDEX; SLEEP QUALITY; THERAPEUTIC DRUG MONITORING;

ADULT; ALLELES; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BENZOXAZINES; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; REVERSE TRANSCRIPTASE INHIBITORS; SLEEP; TREATMENT OUTCOME;

EID: 84893910819     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1177/0956462413498581     Document Type: Article

References (35)

1. Staszewski S,Morales-Ramirez J,Tashima KT, et al.Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults.Study 006 Team. N Engl J Med. 1999;341:1865-1873.
2. Clifford DB,Evans S,Yang Y, et al.Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.Ann Intern Med. 2005;143:714-721.
3. van Luin M,Bannister WP,Mocroft A, et al.EuroSIDA Study Group. Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study.Antivir Ther. 2009;14:75-83.
4. Scourfield A,Zheng J,Chinthapalli S, et al.Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals.AIDS. 2012;26:1399-1401.
5. Gallego L,Barreiro P,del Río R, et al.Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz.Clin Infect Dis. 2004;38:430-432.
6. Moyle G,Fletcher C,Brown H, et al.Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen.HIV Med. 2006;7:243-247.
7. Rodriguez-Novoa S,Barreiro P,Rendón A, et al.Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects.Clin Infect Dis. 2005;40:1358-1361.
8. Haas DW,Ribaudo HJ,Kim RB, et al.Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.AIDS. 2004;18:2391-2400.
9. Xu B,Gui L,Lee SS, et al.The genetic variability of CYP2B6 polymorphisms in four southern Chinese populations.World J Gastroenterol. 2007;13:2100-2103.
10. To KW,Liu ST,Cheung SW, et al.Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese.Ther Drug Monit. 2009;31:527-530.
11. Fumaz CR,Muñoz-Moreno JA,Moltó J, et al.Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.J Acquir Immune Defic Syndr. 2005;38:560-565.
12. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf (accessed 22 April 2013).
13. Buysse DJ,Reynolds CF,Monk TH, et al.The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research.Psychiatry Res. 1989;28:193-213.
14. Tsai PS,Wang SY,Wang MY, et al.Psychometric evaluation of the Chinese version of the Pittsburgh Sleep Quality Index (CPSQI) in primary insomnia and control subjects.Qual Life Res. 2005;14:1943-1952.
15. Hanley JA,Negassa A,Edwardes MD, et al.Statistical analysis of correlated data using generalized estimating equations: an orientation.Am J Epidemiol. 2003;157:364-375.
16. Kenedi CA,Goforth HW.A systematic review of the psychiatric side-effects of efavirenz.AIDS Behav. 2011;15:1803-1818.
17. Fischl MA,Ribaudo HJ,Collier AC, et al.A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.J Infect Dis. 2003;188:625-634.
18. Marzolini C,Telenti A,Decosterd LA, et al.Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.AIDS. 2001;15:71-75.
19. Gutiérrez F,Navarro A,Padilla S, et al.Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.Clin Infect Dis. 2005;41:1648-1653.
20. Read TR,Carey D,Mallon P, et al.Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial.AIDS. 2009;23:2222-2223.
21. Lee KA,Gay C,Portillo CJ, et al.Types of sleep problems in adults living with HIV/AIDS.J Clin Sleep Med. 2012;8:67-75.
22. Núñez M,González de Requena D,Gallego L, et al.Higher efavirenz plasma levels correlate with development of insomnia.J Acquir Immune Defic Syndr. 2001;28:399-400.
23. Norman SE,Chediak AD,Freeman C, et al.Sleep disturbances in men with asymptomatic human immunodeficiency (HIV) infection.Sleep. 1992;15:150-155.
24. Darko DF,McCutchan JA,Kripke DF, et al.Fatigue, sleep disturbance, disability, and indices of progression of HIV infection.Am J Psychiatry. 1992;149:514-520.
25. Cruess DG,Antoni MH,Gonzalez J, et al.Sleep disturbance mediates the association between psychological distress and immune status among HIV-positive men and women on combination antiretroviral therapy.J Psychosom Res. 2003;54:185-189.
26. Holzinger ER,Grady B,Ritchie MD, et al.Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.Pharmacogenet Genomics. 2012;22:858-867.
27. Lin AW,Yam WC,Lam HY, et al.Pharmacogenetic screening: HLA-B*5701 vs.CYP2B6 G516T. HIV Med. 2011;12:255-256.
28. Nolan D,Phillips E,Mallal S.Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance.Clin Infect Dis. 2006;42:408-410.
29. Rosen S,Fox MP,Gill CJ.Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review.PLoS Med. 2007;4:e298-e298.
30. Tassie JM,Baijal P,Vitoria MA, et al.Trends in retention on antiretroviral therapy in national programs in low-income and middle-income countries.J Acquir Immune Defic Syndr. 2010;54:437-441.
31. Miller CM,Ketlhapile M,Rybasack-Smith H, et al.Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa.Trop Med Int Health. 2010;15:48-54.
32. Brown DM,Thorne JE,Foster GL, et al.Factors affecting attrition in a longitudinal study of patients with AIDS.AIDS Care. 2006;18:821-829.
33. Pérez-Molina JA.Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients.HIV Clin Trials. 2002;3:279-286.
34. Spaulding A,Rutherford GW,Siegfried N.Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals.Cochrane Database Syst Rev. 2010;8:CD008651-CD008651.
35. Martinez-Picado J,Negredo E,Ruiz L, et al.Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial.Ann Intern Med. 2003;139:81-89.